Alpha 2.0
Login Register
» Specialties » Hematology

Hematology

Hematology is the study of blood, blood-forming organs, and blood diseases. It involves diagnosing and treating conditions such as anemia, leukemia, and clotting disorders. Hematologists analyze blood samples, manage disorders related to red and white blood cells, platelets, and bone marrow, and develop treatment plans to address various hematological conditions.
Overview
Name Hematology
Journals 160
Journals
Journal h-index
1. Blood 525
2. Leukemia 219
3. Journal of Thrombosis and Haemostasis : Jth 212
4. British Journal of Haematology 208
5. Thrombosis and Haemostasis 206
6. Haematologica 165
7. Transfusion 150
8. Journal of Hematology & Oncology 144
9. Critical Reviews in Oncology/hematology 144
10. American Journal of Hematology 130
Full List
Recent Articles
1.
Unconventional interaction of the zebrafish thrombopoietin receptor with Mapk14a determines thrombocyte development and function
Thakkar K, Naseer S, Chowdhury S, Mondal S, Shrivastva S, Ribeyron L, et al.
J Thromb Haemost . 2025 Mar; PMID: 40089183
Background: Thrombopoietin receptor signalling permits the thrombocyte lineage development in human, mice as well as zebrafish. While the sequence, structure, signalling, and function of TpoR is well-conserved in humans and...
2.
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Zhao J, Tang B, Shen P, Zeng H, Wei Q
Crit Rev Oncol Hematol . 2025 Mar; :104698. PMID: 40089046
Poly (ADP-ribose) polymerase (PARP) inhibitors have revolutionized the treatment of many cancers. Metastatic castration-resistant prostate cancer (mCRPC) is an area where PARP inhibitors are intensively studied; the efficacy with PARP...
3.
Now where do we STAND with crizanlizumab?
Mendez-Marti S, Thein S
Lancet Haematol . 2025 Mar; PMID: 40088923
No abstract available.
4.
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial
Abboud M, Cancado R, De Montalembert M, Smith W, Rimawi H, Voskaridou E, et al.
Lancet Haematol . 2025 Mar; PMID: 40088922
Background: Crizanlizumab has previously shown efficacy as a potent disease-modifying therapy for alleviating vaso-occlusive crisis in sickle cell disease. The SUSTAIN study showed a reduction of vaso-occlusive crises in patients...
5.
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs
Collomb E, Bourguignon L, Tichadou A, Roche P, Berton G, Ciccolini J, et al.
Hematol Oncol . 2025 Mar; 43(2):e70057. PMID: 40088477
No abstract available.
6.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv . 2025 Mar; PMID: 40088469
No abstract available.
7.
Complement C5 Inhibition in early onset HELLP Syndrome
Gerber G, Brodsky R, Vaught A
Blood Adv . 2025 Mar; PMID: 40088468
No abstract available.
8.
Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes
Trneny M, Fogliato L, Gardner F, Flinn I, Larouche J, Haioun C, et al.
Blood Adv . 2025 Mar; PMID: 40088467
No abstract available.
9.
Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study
Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital M, Devillier R, et al.
Am J Hematol . 2025 Mar; PMID: 40088036
No abstract available.
10.
Contemporary Topics in Myeloproliferative Neoplasms and Myelodysplastic Syndromes: American Journal of Hematology 100th Volume Anniversary Symposium
Brugnara C, Vannucchi A, Tefferi A
Am J Hematol . 2025 Mar; PMID: 40087835
No abstract available.
Full List